Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2022 Earnings Conference Call February 21, 2023 8:30 AM ET

Company Participants

Luis Sanay - Head-Investor Relations

Jeffrey Dierks - Chief Commercial Officer

Jeffrey Dayno - Interm CEO & Chief Medical Officer

Sandip Kapadia - Chief Financial Officer

Conference Call Participants

Francois Brisebois - Oppenheimer

David Amsellem - Piper Sandler

Chris Howerton - Jefferies

Charles Duncan - Cantor Fitzgerald

Corinne Jenkins - Goldman Sachs

Ami Fadia - Needham

Graig Suvannavejh - Mizuho Securities

Danielle Brill - Raymond James

Operator

Good morning everyone. My name is Todd and I will be your conference operator today. At this time, I would like to welcome everyone to Harmony Biosciences Fourth Quarter and Full Year 2022 Financial Results Conference Call. All participant have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference may be recorded. [Operator Instructions]

I will now turn the call over to Luis Sanay, Head of Investor Relations. Please go ahead.

Luis Sanay

Thank you, operator. Good morning, everyone and thank you for joining us today, as we review Harmony Biosciences’ fourth quarter and full year 2022 financial results and provide a business update. Before we start, I encourage everyone to go to the investors section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying business performance.

Our presenters on today's call are; Dr. Jeffrey Dayno, Interm CEO and Chief Medical Officer; Jeffrey Dierks, Chief Commercial Officer; and Sandip Kapadia, Chief Financial Officer.

Moving on to slide 2. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially and we undertake no obligation to update these statements even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details.

I would now like to turn the call over to Dr. Jeffrey Dayno. Jeff?

Jeffrey Dayno

Thank you, Luis and thank you everyone for joining our conference call today. We delivered another strong quarter in Q4 finishing the year with continued momentum in our commercial business for WAKIX, as well as in the advancement of our clinical development programs for pitolisant. We are excited for 2023 and remain confident in the ongoing execution of our three pillar growth strategy to further evolve harmony into a leading rare disease company focused on delivering innovative therapies for patients living with rare neurological diseases.